• Shopping cart is empty.

    The International Society for Aerosols in Medicine

    David Cipolla

    David Cipolla

    David Cipolla

    Insmed Incorporated  
    Bridgewater, NJ
    USA

    David has more than 25 years of experience in the pharmaceutical industry with a focus on the development of formulation and drug delivery technologies to support pharmaceutical product development.David is currently the VP of Research at Insmed, Inc, where he is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Prior to joining Insmed in 2018, David was VP Preclinical Research at Aradigm (1996 to 2018) covering all phases of product development and before joining Aradigm David worked at Genentech, Inc. (1988 to 1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis in 1993.

     

    David holds a chemical engineering degree from MIT (SB) and UC Davis (MS) and a pharmacy degree from the University of Sydney (PhD). David served as chair of IPAC-RS (2006-2008), chair of the ISAM Regulatory Affairs Working Group (2009-2010; 2017-2019) and ISAM Board Member (2011-2015).He is on the editorial board of the Journal of Aerosol Medicine and Pulmonary Drug Delivery (2008-present), the Inhalation Magazine (2008-present) and Pharmaceutical Patent Analyst (2012-present).